The titles of the posters are “Lung tissue type selected amniotic fluid derived mesenchymal stem cells for treatment of bleomycin induced pulmonary fibrosis in a rat model” and “Extracellular Vesicles (EVs) derived from amniotic fluid mesenchymal stem cells selected by skin tissue type markers reduce inflammation”.
 
This new data provides insights on Amniotics cell sorting processes and validation of the selection methods of stem cells that are specific for the lung and for skin respectively using a bioinformatics approach followed by verification of selected cell surface targets by flow cytometry.
 
In addition, the first poster shows that lung specific stem cells were effective in reducing lung fibrosis in a bleomycin-induced pulmonary fibrosis model. No adverse reactions were observed, and the stem cells were no longer detected in the rats after day 24, supporting that the stem cells were cleared after exerting their effect. The second poster showed that extracellular vesicles derived from skin specific stem cells in high purity and concentration, significantly decreased inflammation in skin, in an in vitro cell activation model.

“We are excited to share our validated stem cell selection process, which has proven effective in extracting stem cells that are highly specific to the organs we are aiming to treat. Moreover, the data on our lung specific stem cells gives us strong support in their potential to treat patients suffering from lung diseases with fibrotic components like idiopathic pulmonary fibrosis. The data on extracellular vesicles, which are also derived from amniotic fluid stem cells, is quite interesting as EVs open a new and potentially faster route to the patients “, says Jan Talts, COO at Amniotics.
 
The posters are presented by Amniotic’s COO Jan Talts on Wednesday May 4, btw 18:30 - 20:00 (Pacific time)/ Thursday May 5, 03.30-05.00 (Central European).